Regeneron Pharmaceuticals (REGN) Stock: Buy, Sell, or Hold?
$955.47
+4.28 (+0.45%)
▲
5d:
+5.65%
30d:
+19.98%
90d:
+18.55%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 30, 2026
0d
Protect REGN Gains
Updated Nov 13, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (24%)
Quality Score
41/100
Position
EXTENDED
30-Day Fair Range
$756.03 – $913.04
Position: EXTENDED
Forward P/E & Valuation
15.4x
FAIR
vs 15.9x historical avg
Wall Street Target
$977.93
+2.4% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$887.04 / $991.73
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: REGN shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$851.77
Based on -2.8% avg growth
INTRINSIC VALUE TODAY
$528.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $955.47, which is considered extended relative to its 30-day fair value range of $756.03 to $913.04. The stock's valuation (Forward PE: 15.4) is in line with its historical norms (15.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This pessimistic expectation contrasts with the company's recent 35.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, REGN is in a strong uptrend. Immediate support is located at $887.04, while resistance sits at $991.73.
Market Sentiment: REGN scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, REGN is in a strong uptrend. Immediate support is located at $887.04, while resistance sits at $991.73.
Market Sentiment: REGN scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$756.03 -
$913.04
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
23.8%
Trading Range & Key Levels
30-Day Trading Range
$756.03 -
$913.04
Current vs Trading Range
EXTENDED
Support Level
$887.04
Resistance Level
$991.73
Current Trend
Strong Uptrend
Technical data as of
Nov 13, 2026
Protect Your Profits
Holding REGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($977.93)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
15.38
Wall Street Target
$977.93
(+2.4%)
Revenue Growth (YoY)
36.3%
Earnings Growth (YoY)
35.5%
Profit Margin
28.5%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
15.4 vs 15.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$944.96
(-1%)
2-Year Target
$934.57
(-2%)
3-Year Target
$924.29
(-3%)
3-Yr Target (if PE normalizes)
(PE: 15→16)
$955.53
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: -9.6%)
$910.33
(+-5%)
Base:
(SPY PE: 15.4, Growth: -9.6%)
$704.98
(-26%)
Bear:
(PE: 13.1, Growth: -9.6%)
$599.24
(-37%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 21.03 | Current EPS (TTM): $45.24
Bull Case
$1436.80
(+50%)
Analyst growth 37.3%, PE expands to 23.1
Base Case
$1306.18
(+37%)
Market implied 37.3%, PE stable at 21.0
Bear Case
$646.81
(-32%)
Severe decline -20.0%, PE contracts to 17.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.4 to 15.9
Stabilization Target:
$987.77
(+3.4%)
PE Expansion Potential:
+3.4%
Share REGN Analysis
Share this live REGN analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (REGN)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Regeneron's POTS Phase 2 trial shows promising results for baloncibart, a first-in-class NPR1 blocking antibody, which reduced orthostatic heart rate and improved symptoms in patients.
Key Retail Themes:
Positive clinical trial results for baloncibart in POTS patients
Potential for FDA approval and market expansion for Regeneron
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 5:46 AM ET
Data refreshes hourly during market hours. Next update: 6:46 AM
Data refreshes hourly during market hours. Next update: 6:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 60 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 40 SELL |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 36 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 39 SELL |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 63 BUY |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive REGN Research Pages
